REZILIENT1 Trial of Zipalertinib in NSCLC Meets Primary Endpoint | Docwire News
The phase 2b REZILIENT1 trial is evaluating zipalertinib in patients with previously treated non–small cell lung cancer who have an EGFR exon 20 insertion mutation.
The phase 2b REZILIENT1 trial is evaluating zipalertinib in patients with previously treated non–small cell lung cancer who have an EGFR exon 20 insertion mutation.
Get tickets online for Oncology Brothers AIO at ASCO GU 2025 here.
The updated statement covers significant updates that have emerged over the past decade, including the importance of palliative care principles to all levels of care…
Aliya Omer, AstraZeneca, talks about data that backs the efficacy of olaparib in treating high-risk early breast cancer.
∗Address for correspondence: Dr Julien Dreyfus, Department of Cardiology, Centre Cardiologique du Nord, 32-36 rue des moulins gémeaux, 93200 Saint-Denis, France. E-mail: E-mail Address: [email…
Data support the use of rituximab over watchful waiting in front-line therapy for patients with low-tumor-burden follicular lymphoma, study concludes.
Health care professionals should identify couples who have difficulty coping and adapting, and consider couple-centered dyadic resilience interventions to improve these behaviors.
Nature Food – Canada’s Food Guide recommends greater consumption of plant protein foods, but replacing animal with plant protein sources might have important consequences. Based…
In this week’s issue of our environmental newsletter, we find out how much longer you could live (and the emissions you could cut) if you…
Oncodaily – Oncology News, Insights, Stories
A secondary analysis of Diuretic Comparison Project trial data sought to understand the effects of thiazide diuretics chlorthalidone versus hydrochlorothiazide on kidney outcomes.